血管紧张素受体脑啡肽酶抑制对三种方法检测B型利钠肽水平影响的比较:PROVE-HF研究
在130例射血分数降低的心力衰竭患者中,于沙库巴曲/缬沙坦治疗前及治疗52周内多次检测B型利钠肽(BNP),比较Siemens、Abbott和Quidel三种免疫分析法。结果显示Quidel和Abbott(N端捕获抗体)检测的BNP下降幅度显著大于Siemens(C端捕获抗体),差异在12周后才具统计学意义。
要点
- 沙库巴曲/缬沙坦治疗后,不同BNP免疫分析法检测的下降幅度存在差异。
- N端捕获抗体法(Quidel、Abbott)的BNP下降显著大于C端捕获抗体法(Siemens)。
- BNP检测差异在治疗12周后才具有统计学意义。
核心结论
- 启动沙库巴曲/缬沙坦后,BNP检测结果可能因所用免疫分析法不同而存在适度差异,尤其在治疗数月后。
研究设计与样本
- PROVE-HF研究纳入130例射血分数降低的心力衰竭患者,在沙库巴曲/缬沙坦治疗前及治疗52周内重复采血,用Siemens、Abbott和Quidel三种BNP免疫分析法检测。
主要发现
- 基线BNP中位数:Siemens法133 ng/L,Abbott法127 ng/L,Quidel法141 ng/L。
- Quidel和Abbott(均为N端捕获抗体)检测的BNP下降显著大于Siemens(C端捕获抗体),P=0.009和P<0.001。
- 与基线差异在12周后才具统计学意义:Quidel平均-10.1%,Abbott平均-14.3%;12周前差异无统计学意义:Quidel平均-4.5%,Abbott平均-6.0%。
临床怎么用
- 临床解读沙库巴曲/缬沙坦治疗后的BNP变化时,需考虑所用检测方法可能影响下降幅度。
局限性
- 这些差异是否与脑啡肽酶介导的抗体结合位点降解有关,尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several different B-type natriuretic peptide (BNP) assays are used clinically for diagnostic and prognostic evaluation of heart failure (HF). BNP binds weakly to neprilysin and is cleaved in multiple areas adjacent to the binding sites for the antibodies used in these immunoassays. We assessed the changes in BNP following neprilysin inhibition as measured by 3 immunoassays that recognize different epitopes. METHODS: Among 130 participants with HF with reduced ejection fraction, blood was collected prior to treatment with sacubitril/valsartan (sac/val) and then repeatedly measured through 52 weeks of treatment. BNP concentrations were measured with 3 widely used BNP assays (Siemens, Abbott, and Quidel). RESULTS: Study participants had a mean age of 65 ± 13 years and 76% were men. The median BNP concentration at baseline was 133 ng/L by the Siemens assay, 127 ng/L by the Abbott assay, and 141 ng/L by the Quidel assay. Following initiation of sac/val, there were significantly greater declines in BNP measured by Quidel and Abbott (P = 0.009 and P < 0.001), respectively (both with N-terminal capture antibodies), compared to Siemens (with C-terminal capture antibodies). The difference from baseline was not statistically significant until after week 12 (mean -10.1% for Quidel and -14.3% for Abbott) compared to non-significant differences before 12 weeks (mean -4.5% for Quidel and -6.0% for Abbott). CONCLUSIONS: Following initiation of sac/val, BNP measurements may modestly differ depending on the assay method used, particularly after a few months of treatment. Whether these differences relate to neprilysin-mediated degradation of antibody binding sites deserves further study. STUDY REGISTRATION: PROVE-HF ClinicalTrials.gov Identifier: NCT02887183.
引用
- Myhre PL, Prescott MF, Claggett B, et al. Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. Clin Chem. 2022. PMID: 36103292. doi:10.1093/clinchem/hvac148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。